Evidence map›Paper›PMID 30919407›Full record

Trial reportThe British journal of dermatology2019

The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study.

R Bissonnette, C Maari, S Forman, N Bhatia, M Lee, J Fowler, S Tyring, D Pariser, H Sofen, S Dhawan and 8 more

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The British journal of dermatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 9 pooled it
15.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 9 syntheses or guidelines pooled it, 126 citations in OpenAlex.

  1. Large-scale meta-analysis of infection risk with JAK-STAT inhibitors in 29,000 patients.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Infection risk with JAK inhibitors in dermatoses: a meta-analysis.International journal of dermatology · 2025
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Systemic treatments for eczema: a network meta-analysis.The Cochrane database of systematic reviews · 2020
    Pooled it
  9. STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review.Journal of experimental & clinical cancer research : CR · 2019
    Pooled it
  10. Trial
  11. Trial
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. From Pathways to Patients in Atopic Dermatitis: Advanced Systemic Therapies.International journal of molecular sciences · 2025
    Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 9 institutions in 2 countries.

R BissonnetteInnovaderm Research Inc., 1851 Sherbrooke Street East, Suite 502, Montreal, H2K 4L5, Quebec, Canada.ORCID 0000-0001-5927-6587
C MaariInnovaderm Research Inc., 1851 Sherbrooke Street East, Suite 502, Montreal, H2K 4L5, Quebec, Canada.
S FormanForward Clinical Trials, Inc., 4915 Ehrlich Road, Tampa, 33624, FL, U.S.A.
N BhatiaTherapeutics Clinical Research, 9025 Balboa Avenue, Suite 105, San Diego, 92123, CA, U.S.A.
M LeeProgressive Clinical Research, P.A., LLC, 1973 North West Loop 410, Suite 106, San Antonio, 78213, TX, U.S.A.
J FowlerDermatology Specialists Research, 3810 Springhurst Boulevard, Suite 130, Louisville, 40241, KY, U.S.A.
S TyringCenter for Clinical Studies, University of Texas Health Science Center, 451 North Texas Avenue, Houston, 77598, TX, U.S.A.
D PariserDepartment of Dermatology, Eastern Virginia Medical School and Virginia Clinical Research Inc., 6160 Kempsville Circle, Suite 200A, Norfolk, 23502, VA, U.S.A.
H SofenDermatology Research Associates, 8930 South Sepulveda Boulevard, Los Angeles, 90045, CA, U.S.A.
S DhawanCenter for Dermatology Clinical Research Inc., 2557 Mowry Avenue, Suite 21 and 25, Fremont, 94538, CA, U.S.A.
M ZookOlympian Clinical Research, 1201 South Myrtle Avenue, Clearwater, 33756, FL, U.S.A.
D J ZammitAsana BioSciences, LLC, 997 Lenox Drive, Suite 220, Princeton Pike Corporate Center, Lawrenceville, 08648, NJ, U.S.A.
H UsanskyAsana BioSciences, LLC, 997 Lenox Drive, Suite 220, Princeton Pike Corporate Center, Lawrenceville, 08648, NJ, U.S.A.
L DenisAsana BioSciences, LLC, 997 Lenox Drive, Suite 220, Princeton Pike Corporate Center, Lawrenceville, 08648, NJ, U.S.A.
N RaoAsana BioSciences, LLC, 997 Lenox Drive, Suite 220, Princeton Pike Corporate Center, Lawrenceville, 08648, NJ, U.S.A.
T SongIcahn School of Medicine at Mount Sinai, 1425 Madison Avenue, Icahn Building 13-76, New York, 10029, NY, U.S.A.
A B PavelIcahn School of Medicine at Mount Sinai, 1425 Madison Avenue, Icahn Building 13-76, New York, 10029, NY, U.S.A.
E Guttman-YasskyIcahn School of Medicine at Mount Sinai, 1425 Madison Avenue, Icahn Building 13-76, New York, 10029, NY, U.S.A.ORCID 0000-0002-9363-324X
Asana Biosciences (United States) · USIcahn School of Medicine at Mount Sinai · USInnovaderm (Canada) · CACenter for Clinical Research (United States) · USCenter for Clinical Studies · USDermatology Specialists · USEastern Virginia Medical School · USProgressive Clinical Research · USTherapeutics Clinical Research · US

Funding

Asana BioSciences, LLC
6 · The paper itself

Abstract

backgroundASN002 is an oral dual inhibitor of Janus kinase and spleen tyrosine kinase, which are involved in the pathogenesis of atopic dermatitis (AD) through their regulatory role on T helper (Th)1, Th2 and Th17/Th22 pathways.

objectivesThe objectives of this study were to evaluate the efficacy, safety, pharmacokinetics and effects on systemic biomarkers of ASN002 in patients with moderate-to-severe AD. Methods A total of 36 patients with moderate-to-severe AD were randomized (3 : 1) to ASN002 or placebo in the phase Ib study. Three dosage cohorts were studied over a 28-day period (20 mg, 40 mg and 80 mg once daily).

resultsASN002 was superior to placebo for the proportion of patients achieving Eczema Area and Severity Index (EASI) 50 (20 mg 20%, P = 0·93; 40 mg 100%, P = 0·003; 80 mg 83%, P = 0·03; placebo 22%), EASI 75 (20 mg 0%, P = 0·27; 40 mg 71%, P = 0·06; 80 mg 33%, P = 0·65; placebo 22%) and in change from baseline in pruritus (20 mg -1·3 ± 2·1, P = 0·81; 40 mg -3·1 ± 2·7, P = 0·27; 80 mg -4·7 ± 2·1, P = 0·01; placebo -1·6 ± 1·8). Adverse events were generally mild and similar across all groups. ASN002 showed dose-dependent plasma exposure with low interpatient variability, significantly downregulated several serum biomarkers involved in Th1, Th2 and Th17/Th22 immunity, and decreased the atherosclerosis-associated biomarker E selectin/SELE.

conclusionsIn patients with moderate-to-severe AD, ASN002 showed strong efficacy with rapid onset of action and associated improvements in systemic inflammation.

Indexed as

AcetonitrilesAdultBiomarkersDermatitis, AtopicDose-Response Relationship, DrugDouble-Blind MethodDown-RegulationE-SelectinFemaleHumansJanus Kinase InhibitorsJanus KinasesMaleMiddle AgedPiperidinesPlacebosAcetonitrilesBiomarkersE-SelectingusacitinibJanus Kinase InhibitorsJanus KinasesPiperidinesPlacebosPyridazinesSELE protein, humanSyk KinaseSYK protein, human

Identifiers

PMID30919407
PMCPMC6850605
OpenAlexW2932169608

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.